ArticleScientific reports2016
'Artilysation' of endolysin λSa2lys strongly improves its enzymatic and antibacterial activity against streptococci.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- Inhalable bacteriophage endolysins: a novel therapeutic strategy for drug-resistant bacterial pulmonary infections - a comprehensive review.Annals of medicine · 2026Review
- Polycationic Peptide Engineering of Phage Endolysins Expands Host Range and Enhances Antibacterial and Antibiofilm Activities Against Bacillus Species.Biotechnology and bioengineering · 2026Article
- Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica.Applied microbiology and biotechnology · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- Article
- Dual-Receptor Recognition, Lysis Inhibition, Endolysin Release, and Reaction-Diffusion as Alternative Explanations. Comment on Rojero et al. Bypassing Evolution of Bacterial Resistance to Phages: The Example of Hyper-Aggressive Phage 0524phi7-1.International journal of molecular sciences · 2025Article
- Novel delivery systems for phages and lysins in the topical management of wound infections: a narrative review.Frontiers in microbiology · 2025Review
- LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria.Microbial biotechnology · 2024Article
- Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review.Acta veterinaria Scandinavica · 2024Review
- Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model.Journal of biomedical science · 2024Article
- Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens.Microbial biotechnology · 2023Article
- Characterization and Engineering Studies of a New Endolysin from theInternational journal of molecular sciences · 2023Article
- Article
- Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins.Scientific reports · 2022Article
- Engineering a Lysin with Intrinsic Antibacterial Activity (LysMK34) by Cecropin A Fusion Enhances Its Antibacterial Properties against Acinetobacter baumannii.Applied and environmental microbiology · 2022Article
- Bacteriophage-Mediated Control of Biofilm: A Promising New Dawn for the Future.Frontiers in microbiology · 2022Review
- Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.Antibiotics (Basel, Switzerland) · 2021Review
- Optimized Silica-Binding Peptide-Mediated Delivery of Bactericidal Lysin Efficiently PreventsInternational journal of molecular sciences · 2021Article
- Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics.Infectious diseases and therapy · 2021Review
- Phage-Encoded Endolysins.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endolysins constitute a promising class of antibacterials against Gram-positive bacteria. Recently, endolysins have been engineered with selected peptides to obtain a new generation of lytic proteins, Artilysins, with specific activity against Gram-negative bacteria. Here, we demonstrate that artilysation can also be used to enhance the antibacterial activity of endolysins against Gram-positive bacteria and to reduce the dependence on external conditions. Art-240, a chimeric protein of the anti-streptococcal endolysin λSa2lys and the polycationic peptide PCNP, shows a similar species specificity as the parental endolysin, but the bactericidal activity against streptococci increases and is less affected by elevated NaCl concentrations and pH variations. Time-kill experiments and time-lapse microscopy demonstrate that the killing rate of Art-240 is approximately two-fold higher compared to wildtype endolysin λSa2lys, with a reduction in viable bacteria of 3 log units after 10 min. In addition, lower doses of Art-240 are required to achieve the same bactericidal effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.